321.92
price down icon2.74%   -9.07
after-market After Hours: 321.92
loading
Praxis Precision Medicines Inc stock is traded at $321.92, with a volume of 448.98K. It is down -2.74% in the last 24 hours and up +10.97% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$330.99
Open:
$333.79
24h Volume:
448.98K
Relative Volume:
1.04
Market Cap:
$8.97B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-23.90
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-5.55%
1M Performance:
+10.97%
6M Performance:
+61.50%
1Y Performance:
+784.15%
1-Day Range:
Value
$319.40
$349.01
1-Week Range:
Value
$319.40
$349.01
52-Week Range:
Value
$34.89
$356.00

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name
Name
Praxis Precision Medicines Inc
Name
Phone
617-300-8460
Name
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Name
Employee
10,998
Name
Twitter
Name
Next Earnings Date
2026-05-01
Name
Latest SEC Filings
Name
PRAX's Discussions on Twitter

Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PRAX icon
PRAX
Praxis Precision Medicines Inc
321.92 9.22B 7.46M -303.27M -249.12M -13.47
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
430.14 108.36B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
731.77 78.05B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
775.03 48.74B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
302.11 41.16B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
298.16 33.17B 5.36B 287.73M 924.18M 2.5229

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-26 Initiated Raymond James Strong Buy
Feb-24-26 Initiated Wolfe Research Outperform
Feb-02-26 Initiated Wells Fargo Equal Weight
Dec-15-25 Reiterated Oppenheimer Outperform
Nov-19-25 Initiated BTIG Research Buy
Jun-02-25 Resumed Oppenheimer Outperform
May-07-25 Initiated Chardan Capital Markets Buy
Mar-03-25 Reiterated H.C. Wainwright Buy
Feb-11-25 Initiated Deutsche Bank Buy
Aug-05-24 Initiated Oppenheimer Outperform
Jun-24-24 Initiated Needham Buy
Jun-18-24 Initiated Guggenheim Buy
May-01-24 Initiated Robert W. Baird Outperform
Sep-19-23 Initiated Truist Buy
Jun-06-22 Downgrade Wedbush Outperform → Neutral
Dec-16-21 Initiated H.C. Wainwright Buy
Aug-26-21 Initiated BofA Securities Buy
Apr-26-21 Initiated William Blair Outperform
Nov-11-20 Initiated Wedbush Outperform
Nov-10-20 Initiated Cowen Outperform
Nov-10-20 Initiated Evercore ISI Outperform
Nov-10-20 Initiated Piper Sandler Overweight
View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

pulisher
Apr 27, 2026

Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co

Apr 27, 2026
pulisher
Apr 27, 2026

Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology - Insider Monkey

Apr 27, 2026
pulisher
Apr 26, 2026

Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey

Apr 26, 2026
pulisher
Apr 26, 2026

Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

Praxis Precision gains as lead asset accepted for FDA review - MSN

Apr 26, 2026
pulisher
Apr 25, 2026

(PRAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 25, 2026
pulisher
Apr 24, 2026

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Apr 24, 2026
pulisher
Apr 24, 2026

Praxis Precision Medicines (PRAX) Projected to Post Earnings on Friday - MarketBeat

Apr 24, 2026
pulisher
Apr 23, 2026

Praxis Precision Medicines (PRAX): One of the Best Upside Stocks - Insider Monkey

Apr 23, 2026
pulisher
Apr 23, 2026

Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN

Apr 23, 2026
pulisher
Apr 23, 2026

PRAX (Praxis Precision Medicines Inc.) shares rise nearly 7 percent despite wider than expected Q4 2025 per share loss.Stability Report - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026
pulisher
Apr 22, 2026

5 Best Upside Stocks to Buy According to Analysts - Insider Monkey

Apr 22, 2026
pulisher
Apr 22, 2026

LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $567 - Moomoo

Apr 22, 2026
pulisher
Apr 21, 2026

Praxis Precision Medicines (PRAX) Is Up 8.1% After FDA Accepts Ulixacaltamide NDA for Essential Tremor - simplywall.st

Apr 21, 2026
pulisher
Apr 21, 2026

Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo

Apr 21, 2026
pulisher
Apr 18, 2026

LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $545 - 富途牛牛

Apr 18, 2026
pulisher
Apr 18, 2026

Massachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Apr 18, 2026
pulisher
Apr 17, 2026

Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) - MSN

Apr 17, 2026
pulisher
Apr 16, 2026

Needham Raises Price Target for Praxis Precision Medicine (PRAX) - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Why is Praxis Precision stock soaring Tuesday? - MSN

Apr 16, 2026
pulisher
Apr 16, 2026

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1%Time to Sell? - MarketBeat

Apr 16, 2026
pulisher
Apr 15, 2026

Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $437 - Moomoo

Apr 15, 2026
pulisher
Apr 15, 2026

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating - marketscreener.com

Apr 15, 2026
pulisher
Apr 15, 2026

JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - 富途牛牛

Apr 15, 2026
pulisher
Apr 14, 2026

PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus

Apr 14, 2026
pulisher
Apr 14, 2026

FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor By Investing.com - Investing.com South Africa

Apr 14, 2026
pulisher
Apr 14, 2026

FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia

Apr 14, 2026
pulisher
Apr 14, 2026

Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks

Apr 14, 2026
pulisher
Apr 14, 2026

FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan

Apr 14, 2026
pulisher
Apr 14, 2026

Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK

Apr 14, 2026
pulisher
Apr 14, 2026

Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com South Africa

Apr 14, 2026
pulisher
Apr 14, 2026

Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga

Apr 14, 2026
pulisher
Apr 14, 2026

Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com UK

Apr 14, 2026
pulisher
Apr 14, 2026

Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com

Apr 14, 2026
pulisher
Apr 14, 2026

Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com South Africa

Apr 14, 2026
pulisher
Apr 14, 2026

Praxis Precision Medicines stock rating reiterated at Buy by BTIG By Investing.com - Investing.com India

Apr 14, 2026
pulisher
Apr 14, 2026

Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo

Apr 14, 2026

Praxis Precision Medicines Inc Stock (PRAX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Praxis Precision Medicines Inc Stock (PRAX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nemiroff Alex
General Counsel and Secretary
Nov 20 '25
Sale
193.09
25,130
4,852,256
20,832
Mastrocola Lauren
Principal Accounting Officer
Nov 20 '25
Option Exercise
61.12
13,600
831,257
24,042
Mastrocola Lauren
Principal Accounting Officer
Nov 20 '25
Sale
192.08
13,600
2,612,244
10,442
$27.77
price down icon 0.29%
$49.54
price down icon 0.22%
$102.06
price up icon 0.00%
$134.94
price down icon 0.76%
$144.83
price up icon 9.99%
ONC ONC
$298.16
price down icon 0.25%
Cap:     |  Volume (24h):